The effectiveness of stem cell‑derived extracellular vesicles therapy for intrauterine adhesions: a meta-analysis of preclinical studies
Sun Y., Luo Y., Ning J., Chai Y., Chen J., Xiao F.
Meta-analysis, published in Reprod Biol Endocrinol (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- Reprod Biol Endocrinol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40804676
- PMCID
- PMC12345020
- DOI
- 10.1186/s12958-025-01448-2
Abstract (original English)
BACKGROUND: The therapeutic potential of stem cell-derived extracellular vesicles (EVs) for intrauterine adhesions (IUA) has attracted increasing preclinical investigation, yet a comprehensive and up-to-date meta-analysis is currently lacking. Before moving forward with clinical applications, it is essential to fully understand the impact of stem cell-derived EVs on IUA. METHODS: PubMed, EMBASE, Cochrane Library, Web of Science were searched up to May 19th 2025. Trial sequential analysis was conducted to evaluate outcomes, while sensitivity analysis and publication bias assessment were conducted using Stata 14. RESULTS: Across 26 studies (899 animals), our analyses have uncovered several important findings as the following: stem cell-derived EVs significantly improved the number of endometrial glands (SMD = 3.78; 95% CI: 2.62 ~ 4.93; P < 0.00001); endometrial thickness (SMD = 2.65; 95% CI: 1.90 ~ 3.40; P < 0.00001) and the number of embryos (SMD = 2.00; 95% CI: 1.02 ~ 2.97; P = 0.0004); fibrosis reduction (SMD = -3.25; 95% CI: -4.24~ -2.26; P < 0.00001) in IUA animal models. EVs downregulated fibrosis markers (TGF-β1, α-SMA, Col-1) and upregulated vascularization (VEGF) and proliferation (Ki67) genes. CONCLUSIONS: Stem cell-derived EVs demonstrate safety and efficacy in treating IUA animal models, with potential improvements in fertility outcomes.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.